Document is current
Any future updates will be listed below
-
Authors
Calvert, Melanie https://orcid.org/0000-0002-1856-837X
Kamudoni, Paul
Yap, Christina https://orcid.org/0000-0002-6715-2514
Snyder, Claire
Wilson, Roger https://orcid.org/0000-0002-6043-7306
Aiyegbusi, Olalekan Lee https://orcid.org/0000-0001-9122-8251
-
Funding
Funding for this research was provided by:
Merck KGaA
- License Information
-
More Information
Article History
Received: 6 January 2026
Accepted: 22 April 2026
First Online: 19 May 2026
Competing interests
: MJC received personal fees from Astellas, Boehringer Ingelheim, Aparito Ltd, CIS Oncology, Gilead, Halfloop, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK, Pfizer, Vertex, Shionogi, and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. In addition, a family member owns shares in GSK. C.Y. report personal fees from Faron Pharmaceuticals, Bayer, Trogenix and Merck, outside the submitted work. C.S. currently receives personal consulting fees from Movember and Pfizer and previously received personal consulting fees from Shionogi. Dr. Snyder has received travel costs for meeting presentations from Shionogi and Executive Insight Healthcare Consultants. She also receives research funding from Johnson & Johnson through her institution. O.L.A. declares personal fees from Gilead Sciences, Merck, Boehringer Ingelheim, Innovate UK, and GSK. All other authors declare no competing interests.
